FDA slaps China-based API makers with separate warning letters outlining quality, testing shortfalls
Nuowei Chemistry received its write-up after an FDA inspection of its facility in Xuancheng, China, last September, while Innovation Pharmaceutical’s reprimand followed a record request for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results